MPS Pharmaa Limited submitted a mandatory quarterly investor complaint statement to BSE and ASE.
The filing disclosed zero investor complaints pending, received, or resolved for the quarter ended March 2026.
The disclosure was made under SEBI LODR Regulation 13(3) and signed by Company Secretary Pooja Chuni.